Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: Five-year results with epirubicin and ifosfamide

A. Ottaiano, A. De Chiara, F. Fazioli, V. De Rosa, V. Ravo, V. Boccia, G. Botti, A. Petrillo, F. Fiore, S. Mori, N. Mozzillo, V. R. Iaffaioli, G. Apice

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas (STS) may provide some advantages for facilitating the surgical resection of the tumor and for disease control. However its role as induction therapy before surgery should still be proved. Patients and Methods: Twenty-one patients with intermediate/high-grade STS and tumor size ≥5cm were consecutively treated from 1997 to 2001 with neoadjuvant chemotherapy based on epirubicin 60 mg/m 2/day days 1 and 2 and ifosfamide 1.8 gr/m 2/day on days 1 through 5 every three weeks. Evaluation of objective tumor response and toxicity were carried out according to WHO criteria. Results: Nine partial responses were documented; stable disease in 11 patients, progressive disease in one patient. Apart from nine cases of grade 4 neutropenia, the treatment was generally well-tolerated. Twelve patients underwent conservative and limb salvage surgery. Conclusion: This therapeutic approach seems to be effective in facilitating surgery. Neutropenia was the most significant toxicity but it was preventable or medically treatable with G-CSF support.

Original languageEnglish
Pages (from-to)3555-3559
Number of pages5
JournalAnticancer Research
Volume22
Issue number6 B
Publication statusPublished - Nov 2002

Fingerprint

Epirubicin
Ifosfamide
Sarcoma
Drug Therapy
Neutropenia
Neoplasms
Limb Salvage
Granulocyte Colony-Stimulating Factor
Therapeutics

Keywords

  • Epirubicin
  • Ifosfamide
  • Neoadjuvant chemotherapy
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{1a7aefb6f10349eaa29522f51ea901aa,
title = "Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas: Five-year results with epirubicin and ifosfamide",
abstract = "Background: Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas (STS) may provide some advantages for facilitating the surgical resection of the tumor and for disease control. However its role as induction therapy before surgery should still be proved. Patients and Methods: Twenty-one patients with intermediate/high-grade STS and tumor size ≥5cm were consecutively treated from 1997 to 2001 with neoadjuvant chemotherapy based on epirubicin 60 mg/m 2/day days 1 and 2 and ifosfamide 1.8 gr/m 2/day on days 1 through 5 every three weeks. Evaluation of objective tumor response and toxicity were carried out according to WHO criteria. Results: Nine partial responses were documented; stable disease in 11 patients, progressive disease in one patient. Apart from nine cases of grade 4 neutropenia, the treatment was generally well-tolerated. Twelve patients underwent conservative and limb salvage surgery. Conclusion: This therapeutic approach seems to be effective in facilitating surgery. Neutropenia was the most significant toxicity but it was preventable or medically treatable with G-CSF support.",
keywords = "Epirubicin, Ifosfamide, Neoadjuvant chemotherapy, Soft tissue sarcoma",
author = "A. Ottaiano and {De Chiara}, A. and F. Fazioli and {De Rosa}, V. and V. Ravo and V. Boccia and G. Botti and A. Petrillo and F. Fiore and S. Mori and N. Mozzillo and Iaffaioli, {V. R.} and G. Apice",
year = "2002",
month = "11",
language = "English",
volume = "22",
pages = "3555--3559",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas

T2 - Five-year results with epirubicin and ifosfamide

AU - Ottaiano, A.

AU - De Chiara, A.

AU - Fazioli, F.

AU - De Rosa, V.

AU - Ravo, V.

AU - Boccia, V.

AU - Botti, G.

AU - Petrillo, A.

AU - Fiore, F.

AU - Mori, S.

AU - Mozzillo, N.

AU - Iaffaioli, V. R.

AU - Apice, G.

PY - 2002/11

Y1 - 2002/11

N2 - Background: Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas (STS) may provide some advantages for facilitating the surgical resection of the tumor and for disease control. However its role as induction therapy before surgery should still be proved. Patients and Methods: Twenty-one patients with intermediate/high-grade STS and tumor size ≥5cm were consecutively treated from 1997 to 2001 with neoadjuvant chemotherapy based on epirubicin 60 mg/m 2/day days 1 and 2 and ifosfamide 1.8 gr/m 2/day on days 1 through 5 every three weeks. Evaluation of objective tumor response and toxicity were carried out according to WHO criteria. Results: Nine partial responses were documented; stable disease in 11 patients, progressive disease in one patient. Apart from nine cases of grade 4 neutropenia, the treatment was generally well-tolerated. Twelve patients underwent conservative and limb salvage surgery. Conclusion: This therapeutic approach seems to be effective in facilitating surgery. Neutropenia was the most significant toxicity but it was preventable or medically treatable with G-CSF support.

AB - Background: Neoadjuvant chemotherapy for intermediate/high-grade soft tissue sarcomas (STS) may provide some advantages for facilitating the surgical resection of the tumor and for disease control. However its role as induction therapy before surgery should still be proved. Patients and Methods: Twenty-one patients with intermediate/high-grade STS and tumor size ≥5cm were consecutively treated from 1997 to 2001 with neoadjuvant chemotherapy based on epirubicin 60 mg/m 2/day days 1 and 2 and ifosfamide 1.8 gr/m 2/day on days 1 through 5 every three weeks. Evaluation of objective tumor response and toxicity were carried out according to WHO criteria. Results: Nine partial responses were documented; stable disease in 11 patients, progressive disease in one patient. Apart from nine cases of grade 4 neutropenia, the treatment was generally well-tolerated. Twelve patients underwent conservative and limb salvage surgery. Conclusion: This therapeutic approach seems to be effective in facilitating surgery. Neutropenia was the most significant toxicity but it was preventable or medically treatable with G-CSF support.

KW - Epirubicin

KW - Ifosfamide

KW - Neoadjuvant chemotherapy

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0036875142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036875142&partnerID=8YFLogxK

M3 - Article

C2 - 12552955

AN - SCOPUS:0036875142

VL - 22

SP - 3555

EP - 3559

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -